Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921457 | 0.92 | HTR6 (0.35) | PTGDR2HTR6MCHR1SIGMAR1 | |
| SCHEMBL15087611 | 0.91 | BAZ2B (0.35) | PTGDR2HTR6 | |
| SCHEMBL13834659 | 0.91 | HTR6 (0.39) | PTGDR2HTR6KEAP1SIGMAR1 | |
| SCHEMBL6920786 | 0.90 | HTR6 (0.33) | PTGDR2HTR6MCHR1 | |
| SCHEMBL6921310 | 0.90 | HTR6 (0.41) | PTGDR2HTR6KEAP1MCHR1 | |
| SCHEMBL13394713 | 0.87 | HTR6 (0.36) | PTGDR2HTR6MCHR1SIGMAR1 | |
| SCHEMBL6921076 | 0.85 | FNTA (0.41) | PTGDR2HTR6MCHR1 | |
| SCHEMBL6920559 | 0.84 | HTR6 (0.37) | PTGDR2HTR6MCHR1 | |
| SCHEMBL14729246 | 0.83 | HTR6 (0.36) | PTGDR2HTR6SIGMAR1 | |
| SCHEMBL13834547 | 0.82 | HTR6 (0.37) | PTGDR2HTR6MCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| WO-2011038164-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | PTGDR2 114/4885HTR6 22/4885KEAP1 1236/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | PTGDR2 114/4885HTR6 22/4885KEAP1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.